Self-nanomicellizing solid dispersion of edaravone: part II: in vivo assessment of efficacy against behavior deficits and safety in Alzheimer’s disease model

BACKGROUND: Alzheimer’s disease (AD) is a devastating neurodegenerative disorder that lacks any disease-modifying drug for the prevention and treatment. Edaravone (EDR), an approved free radical scavenger, has proven to have potential against AD by targeting multiple key pathologies including amyloi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Drug Des Devel Ther
Autores principales: Parikh, Ankit, Kathawala, Krishna, Li, Jintao, Chen, Chi, Shan, Zhengnan, Cao, Xia, Wang, Yan-Jiang, Garg, Sanjay, Zhou, Xin-Fu
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6042531/
https://ncbi.nlm.nih.gov/pubmed/30022810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S161944
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares